Replies to post #133770 on Biotech Values

[acgood]

to clarify, if I recall correctly-
if, beyond the initial two products, MNTA has another molecule they want to develop in the first three yeats, BAX has the right of first refusal to option it in this deal. Otherwise, MNTA could develop on own or partner to someone else

[HattieTheWitch]

No,Ma'am. Both the 8-K and the CC are clear that the collaboration stops with six, max. Products beyond 6 require fresh negotiations with whoever.

Excellent! Thank you for the correction, kind sir.